Editorial: Vaccination of Special Populations: Protecting the Vulnerable
- PMID: 34938302
- PMCID: PMC8685389
- DOI: 10.3389/fimmu.2021.815550
Editorial: Vaccination of Special Populations: Protecting the Vulnerable
Keywords: immunisation; immunity; infectious diseases; vaccines; vulnerable populations.
Conflict of interest statement
FM-T reports his institution received trial fees from the GSK group of companies, Ablynx, Abott, Jansen, Medimmune, MSD Merck, Novartis, Novavax, Pfizer, Regeneron, Roche, Sanofi Pasteur and Seqirus for activities outside the presented work. FM-T also reports his institution received research grants from AstraZeneca, Jansen, MSD Merck and Pfizer for activities outside the presented work. FM-T also reports having received personal fees / honorarium from Biofabri, Novavax, Sanofi Pasteur, Seqirus, GSK group of companies, MSD Merck and Pfizer for activities outside the presented work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Comment on
- Editorial on the Research Topic Vaccination of Special Populations: Protecting the Vulnerable
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
